
Brexpiprazole’s EU approval extended to include adolescents
The European Commission (EC) has approved Otsuka’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older. The drug was previously approved in the European Union in 2018 for the treatment of schizophrenia in adults. The EC based its approval on… Read More



